Please login to the form below
Clarivate Analytics
This page shows the latest Clarivate Analytics news and features for those working in and with pharma, biotech and healthcare.
Centre for Innovation in Regulatory Science awarded $1.09m Gates Foundation grant
CIRS is a neutral, independent UK-based subsidiary of Clarivate Analytics, which aims to maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and
Latest news
-
DBV refiles peanut allergy immunotherapy in the US
Meanwhile, Clarivate Analytics thinks AR1010 will makes sales of almost $1.2bn at its peak.
-
FDA approves AbbVie’s psoriasis blockbuster-to-be Skyrizi
phototherapy. The IL-23 inhibitor is expected to reach blockbuster sales, with analysts such as Clarivate Analytics predict the drug making $1.74bn in 2023 for AbbVie and its partner Boehringer
-
The year of the blockbuster
forecast and analysis from Clarivate Analytics. ... is chief scientific officer at Clarivate Analytics. 24th June 2018.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Since 2013, the Cortellis Forecast team at Clarivate has applied its proprietary technologies, tools and techniques trusted by its global life sciences customers to produce the Drugs to Watch list, which ... Joan Tur is Cortellis Editor (Forecast Drugs)
-
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook. Clarivate Analytics, through its Centre for Medicines Research (CMR) International group, recently released the 2019 CMR International Pharmaceutical R&D Factbook –providing insights
-
Pharmaceutical innovation in the APAC region
The full report is free to download and is available from Clarivate Analytics.
-
Encouraging signs in biomarker R&D
Sarah Hardison, therapeutic area director from Clarivate Analytics, has also seen an industry response. ... Clarivate Analytics’ Sarah Hardison also acknowledged that industry may focus on cancers with biomarkers, but sees such an approach as an
-
The trials and tribulations of rare opportunities
Rare disease drugs can also generate high revenues, said Garth Ringheim, Therapeutic Area Director, Clarivate Analytics. ... In other instances where data is available for a large number of patient journeys with the rare disease of interest, predictive
More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
